Combination Immunotherapy Treatment for Glioblastoma Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 Therapy (clinicaltrials.gov) - Aug 14, 2026 - P1/2 | N=10 | Not yet recruiting | Sponsor: BreakBio Corp
New P1/2 trial • Brain Cancer • Glioblastoma • Oncology • Solid Tumor
|